GSTM1 and cancer: Among the tested treatments, Mu1 is the most potent NK activator treatment against all cancer cells with highest activity against MCF7 (57.2%, Figure 5B) cells at a ratio of 1 target cells: 3 activated NK cells compared with 42.0% inhibition using 1:1 cell ratio, and 44.6% at 1:2 ratio.